Oseltamavir in ckd
Reading File
Finding Sources
Searching PubMed
oseltamivir AND "chronic kidney disease" AND dosing
Searching the Web
oseltamivir dose adjustment CKD renal impairment GFR guidelines 2024
Reading File
Reading File
I now have comprehensive data from multiple authoritative sources. Here is a full, well-organized answer:
Oseltamivir (Tamiflu) in Chronic Kidney Disease
Why Renal Adjustment Is Needed
Oseltamivir is an oral prodrug converted by hepatic/GI esterases to oseltamivir carboxylate, its active metabolite. Elimination of this metabolite is almost entirely renal (glomerular filtration + tubular secretion). As GFR falls, serum concentrations of oseltamivir carboxylate rise proportionally, increasing the risk of adverse effects (nausea, vomiting, headache, neuropsychiatric events). Probenecid co-administration also reduces renal clearance by ~50% and should be avoided.
- Katzung's Basic and Clinical Pharmacology, 16th Ed: "Serum concentrations of oseltamivir carboxylate increase with declining renal function; therefore, dosage should be adjusted in patients with renal insufficiency."
Dose Adjustment Table (Adults)
Based on FDA prescribing information and the WHO 2024 Clinical Practice Guidelines for Influenza:
Treatment (5-day course)
| CrCl / eGFR | Standard Adult Dose | Adjusted Dose |
|---|---|---|
| > 60 mL/min | 75 mg BD | 75 mg twice daily (no change) |
| > 30-60 mL/min | 75 mg BD | 30 mg twice daily |
| > 10-30 mL/min | 75 mg BD | 30 mg once daily |
| ≤ 10 mL/min (not on dialysis / ESRD) | - | Not recommended (insufficient data) |
| Haemodialysis (HD) | - | 30 mg after each HD session |
| Peritoneal Dialysis (CAPD) | - | 30 mg as a single dose |
Prophylaxis
| CrCl / eGFR | Adjusted Dose |
|---|---|
| > 60 mL/min | 75 mg once daily |
| > 30-60 mL/min | 30 mg once daily (or 75 mg every other day) |
| > 10-30 mL/min | 30 mg every other day |
| ≤ 10 mL/min (not on dialysis) | Not recommended |
| Haemodialysis | 30 mg after alternate HD sessions |
| Peritoneal Dialysis | 30 mg once weekly |
Paediatric Dose Adjustment (> 3 months - 12 years)
| eGFR | Dose |
|---|---|
| > 30 mL/min/1.73 m² | 2 mg/kg/dose twice daily (max 75 mg/dose) |
| 10-30 mL/min/1.73 m² | 2 mg/kg/dose once daily |
| Peritoneal Dialysis | 1 mg/kg/dose weekly |
| Haemodialysis | 1 mg/kg/dose after every other session |
(Based on Schwartz formula GFR estimation)
Special Situations
| Scenario | Recommendation |
|---|---|
| Continuous Renal Replacement Therapy (CRRT) | Dose should be reduced; standard enteral oseltamivir achieves adequate levels via enteral route (Murray & Nadel) |
| Critically ill / ICU | Enteral route provides adequate serum levels; no proven benefit from higher doses |
| Hepatic impairment | No dose adjustment needed for mild-to-moderate impairment (Child-Pugh ≤ 9) |
| Geriatric patients | No adjustment required for age alone |
| Probenecid co-administration | Reduces renal clearance by 50%; avoid combination or monitor closely |
Key Clinical Points
- Give within 48 hours of symptom onset for maximum benefit - shortens illness duration by ~17 hours and reduces complications.
- Take with food - does not impair absorption and reduces nausea/vomiting.
- Zanamivir (inhaled) is an alternative in CKD - only 5-15% is renally excreted, making it a lower-risk option when renal dosing is complex. However, it is contraindicated in obstructive airway disease.
- Baloxavir (oral, single dose, weight-based) is another option with a different mechanism - check its own renal data before use.
- Neuropsychiatric adverse effects (delirium, self-injury) have been reported, particularly in adolescents in Japan - monitor, though causality vs. influenza itself is unclear.
Sources: WHO 2024 Influenza Guidelines, FDA Tamiflu prescribing information, Harrison's Principles of Internal Medicine 22E, Katzung's Basic and Clinical Pharmacology 16th Ed, Murray & Nadel's Textbook of Respiratory Medicine.
This is a shared conversation. Sign in to Orris to start your own chat.